Ozempic and Wegovy, Weight Loss Drugs That May Help Menopausal Women

Navigating weight changes during menopause can be challenging. This article explores the effectiveness of Ozempic and Wegovy, weight loss drugs for menopause.

Learn how they might be the key to managing weight gain and achieving a healthier balance during this transformative phase of life.

Menopause is a significant phase in a woman’s life marked by the cessation of menstruation, typically occurring in their late 40s or early 50s. One notable challenge many women face during this transitional period is weight gain.

This phenomenon can be attributed to hormonal changes, particularly a decline in estrogen levels and an increase in insulin resistance. Collectively known as hormonal weight gain, these factors contribute to alterations in:

• Body composition
• Fat distribution
• Metabolism

Estrogen and Weight Gain

Estrogen, a key female sex hormone, regulates metabolism and body weight. As women approach menopause, their estrogen levels decrease, leading to fat redistribution from the hips and thighs to the abdominal region.

This shift is associated with an increased risk of visceral fat accumulation, linked to various metabolic complications, including insulin resistance and inflammation.

Insulin Resistance and Weight Gain

Insulin resistance, another factor contributing to menopausal weight gain, is when the body’s cells become less responsive to insulin, leading to elevated blood sugar levels. This can result in increased fat storage, particularly in the abdominal area.

The interplay between low estrogen levels and insulin resistance creates a challenging environment for women during menopause, making them more prone to weight gain.

Menopause Hunger

Furthermore, menopausal women often experience changes in hunger hormones, such as leptin and ghrelin. Leptin, responsible for signaling fullness, tends to decrease, while ghrelin, which stimulates appetite, increases.

This imbalance in hunger hormones can lead to menopause hunger, making women more susceptible to overeating and weight gain.

Several weight loss drugs are available for individuals struggling with obesity, and some of these can be particularly beneficial for women going through menopause.

Commonly prescribed medications include:

• Orlistat
• Phentermine
• Liraglutide

Orlistat works by blocking the absorption of dietary fats in the intestines, leading to reduced calorie intake. Phentermine is an appetite suppressant that affects the central nervous system, reducing the feeling of hunger.

On the other hand, liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, regulates appetite and promotes weight loss by slowing gastric emptying.

Among these drugs, semaglutide, marketed under the names Ozempic and Wegovy, has gained prominence for its effectiveness in managing weight, especially in menopausal women. Like liraglutide, semaglutide also belongs to the GLP-1 receptor agonist class yet has shown much more promising results in weight loss.

Wegovy operates through the activation of GLP-1 receptors.

GLP-1 is a natural hormone released in response to food intake, and it plays a crucial role in regulating glucose levels and appetite. Wegovy mimics the action of GLP-1, exerting its effects on diabetes and chronic weight management.

Initially approved for treating diabetes under Ozempic, Wegovy increases insulin production and reduces glucagon secretion, improving blood sugar control.

However, its efficacy goes beyond glycemic control.

Wegovy also influences appetite and satiety regulation, making it a suitable option for addressing the weight-related challenges faced by menopausal women.

In menopausal women, Wegovy addresses hormonal weight gain by controlling insulin resistance and mitigates menopause hunger by regulating appetite and satiety.

By addressing both aspects of weight gain, Wegovy offers a comprehensive approach to managing weight during menopause.

The effectiveness of Wegovy in promoting weight loss can vary from individual to individual.

Weight loss may begin within the first 4 weeks of treatment, but the full effects may take several months or longer to manifest. Studies have shown that over 68 weeks, adults on Wegovy can achieve a weight loss of up to 15%.

Moreover, after 68 weeks of Wegovy, 83% of adults taking Wegovy may experience a weight loss of at least 5% or more.

Clinically significant weight loss is considered to be achieved when an individual loses 10% or more of their initial body weight. Research has demonstrated that in overweight and obese patients, Wegovy resulted in 10.9% of weight loss after 6 months.

This level of weight loss is associated with various metabolic benefits, including insulin sensitivity, blood pressure, and lipid profile improvements.

The duration for which menopausal women can stay on Wegovy depends on individual tolerance and the assessment of healthcare providers. The most extended duration of treatment with semaglutide has been 68 weeks. Wegovy has demonstrated safety and tolerability with minimal and mild side effects during this period.

There is no evidence to suggest that Wegovy directly affects natural estrogen levels in menopausal women. Semaglutide primarily influences insulin and glucagon secretion to regulate blood sugar levels and contribute to weight loss.

While Wegovy is not indicated to influence sex hormone levels, including estrogen, caution should be exercised for menopausal women taking hormone replacement therapy (HRT).

Estradiol, commonly used in HRT, may interfere with blood glucose control and reduce the effectiveness of semaglutide and other diabetic medications.

Individuals on HRT must monitor blood sugar levels closely, and they may require dose adjustments of diabetic medications during and after treatment with estradiol.

While Wegovy has shown effectiveness in promoting weight loss, weight regain is likely after discontinuation. This highlights the necessity of lifestyle changes, such as a balanced diet and regular physical activity, alongside medication for long-term weight management.

Semaglutide is safe and effective for weight loss in people with and without type 2 diabetes.

However, to obtain a prescription for Wegovy, individuals must meet specific health-related criteria. Healthcare providers will assess factors such as BMI (Body Mass Index) and overall health before prescribing Wegovy for weight management.

Non-diabetic, menopausal women may receive Wegovy if they meet the specified criteria and if the medication is a suitable option for their weight management needs.

While Wegovy can be an effective tool for weight management, certain groups of menopausal women should avoid taking this medication. These include:

• Pregnant or breastfeeding women: The safety of Wegovy during pregnancy and breastfeeding has not been established, and therefore, it is typically not recommended for women in these stages.
• Individuals with a history of thyroid cancer: Wegovy should not be given to anyone who has a personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2) or medullary thyroid cancer (MTC).
• People with a history of pancreatitis: Individuals with a history of pancreatitis or a predisposition to pancreatitis should avoid Wegovy.
• Patients with severe gastrointestinal diseases: Individuals with severe gastrointestinal diseases, such as gastroparesis, should exercise caution or avoid Wegovy, as it may exacerbate these conditions.

Yunique Medical provides FUNCTIONAL MEDICINE for optimized health and performance. We offer customized, scientifically advanced treatments including menopause treatments in Ocala, Port Orange, and The Villages, to create a new state of human thriving. Why be ordinary when you can be optimal?

HUMAN 2.0 begins here!

Contact us to schedule your FREE consultation at one of our three locations in Florida – Ocala, Fruitland Park (The Villages), and Daytona.

UP NEXT:

• Semaglutide Offers Cardiovascular Benefits by Reducing Heart Disease Risks
• Retatrutide: Triple-agonist Peptide for Weight Loss, Obesity, and Diabetes
• Tirzepatide as the Next Game Changer in Weight Loss Drugs